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Interactions with cellular stress pathways are central to the life cycle of many latent viruses. Here, we utilize adeno-associated
virus (AAV) as a model to study these interactions, as previous studies have demonstrated that cellular stressors frequently in-
crease transduction of recombinant AAV (rAAV) vectors and may even substitute for helper virus functions. Since several che-
motherapeutic drugs are known to increase rAAV transduction, we investigated the effect of arsenic trioxide (As2O3), an FDA-
approved chemotherapeutic agent with known effects on several other virus life cycles, on the transduction of rAAV. In vitro,
As2O3 caused a dose-dependent increase in rAAV2 transduction over a broad range of cell lines from various cell types and spe-
cies (e.g., HEK-293, HeLa, HFF hTERT, C-12, and Cos-1). Mechanistically, As2O3 treatment acted to prevent loss of virions from
the perinuclear region, which correlated with increased cellular vector genome retention, and was distinguishable from protea-
some inhibition. To extend our investigation of the cellular mechanism, we inhibited reactive oxygen species formation and de-
termined that the As2O3-mediated increase in rAAV2 transduction was dependent upon production of reactive oxygen species.
To further validate our in vitro data, we tested the effect of As2O3 on rAAV transduction in vivo and determined that treatment
initiated transgene expression as early as 2 days posttransduction and increased reporter expression by up to 10-fold. Moreover,
the transduction of several other serotypes of rAAV was also enhanced in vivo, suggesting that As2O3 affects a pathway used by
several AAV serotypes. In summary, our data support a model wherein As2O3 increases rAAV transduction both in vitro and in
vivo and maintains perinuclear accumulations of capsids, facilitating productive nuclear trafficking.
Adeno-associated virus (AAV), a nonenveloped, single-stranded DNA virus, is a member of the family Parvoviridae
and is classified as a dependovirus, as it requires the presence of a
helper virus, such as adenovirus or herpes simplex virus (HSV), in
order to replicate. In the absence of a helper virus, AAV’s genome
can persist episomally for long time periods (1). The AAV genome
consists of two genes, rep, which encodes the nonstructural pro-
teins, and cap, which encodes the capsid assembly protein and
capsid proteins, flanked by inverted terminal repeats. To make
recombinant AAV (rAAV) vectors, the two viral genes can be en-
tirely removed from the genome with the terminal repeats being
the only cis elements required for vector production (2), allowing
for the examination of the viral transduction pathway leading up
to gene expression. Although no pathogenesis has been linked to
AAV, rAAV plays an important role as a gene delivery vector and
is increasingly used for clinical gene therapy applications (re-
viewed in reference 3).
While there are several naturally occurring serotypes of AAV,
the majority of AAV biology has been elucidated using rAAV se-
rotype 2 (AAV2) vectors. rAAV2 is brought into cells through
receptor-mediated endocytosis (4) and is trafficked through en-
dosomal pathways, along microtubules, to the microtubule orga-
nizing center (MTOC) (5). rAAV2 then escapes from the endo-
some and is trafficked to the nucleus, where it uncoats (6),
exposing the genome for second-strand synthesis and transcrip-
tion. Several steps in the rAAV transduction pathway are ineffi-
cient, including nuclear entry (7) and second-strand synthesis (8,
9), and modifying the environment of the cell can lead to in-
creased efficiency in these steps (6, 8). Specifically, several forms of
cellular stress, including endoplasmic reticulum stress associated
with unfolded protein responses (10), treatment with chemother-
apeutic agents (6, 8), and heat shock (8, 11), have been shown to
positively influence AAV transduction. In fact, our group was the
first to demonstrate that heat shock, hydroxyurea, UV light, and
X-rays are capable of increasing rAAV transduction through a
mechanism involving the enhancement of second-strand DNA
synthesis (8). Two of these treatments, hydroxyurea treatment
and UV light in the presence of simian virus 40 (SV40) T antigen,
were later shown to be able to substitute for helper virus functions
and allow AAV replication in the absence of adenovirus (12).
Moreover, dependence on stress responses in viral life cycles is not
unique to AAV and has in fact been demonstrated to be important
to the reactivation of many latent viruses, from lambda phage (13)
to herpesviruses (14, 15). Although some stress response-depen-
dent reactivation is due to dysregulation of the immune system
(15), some may result from specific changes in the intracellular
environment. In addition, the role of stress in the initial transduc-
tion of viruses other than AAV is less well understood than its role
in latency.
The dependence of the AAV life cycle on cellular stress has been
exploited to attempt to increase the efficiency of rAAV-mediated
gene delivery and improve efficacy in clinical gene therapy appli-
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cations. A number of chemotherapeutic agents have been used to
induce cell stress and enhance rAAV transduction, including pro-
teasome inhibitors such as MG-132, calpain inhibitor I, and bort-
ezomib, DNA synthesis inhibitors such as hydroxyurea and
aphidicolin, and topoisomerase inhibitors such as etoposide and
camptothecin (6, 16–21). Thus far, the leading candidate for en-
hancing rAAV transduction in vivo is bortezomib, a proteasome
inhibitor, which has been demonstrated to increase expression of
a clinically relevant transgene 3- to 6-fold in a large-animal model
(17). Although bortezomib is approved for use in humans, it has
serious toxic side effects, and in rare cases its use can lead to liver
failure and death (17, 22). Therefore, exploring the possibility of
other, less toxic agents to enhance rAAV transduction in vivo re-
mains an advantageous approach.
One specific cellular stressor that has not been examined for its
effect on AAV biology is arsenic trioxide (As2O3). As2O3 was ap-
proved for the treatment of acute promyelocytic leukemia in 2000
(23) and is currently being evaluated for treatment of other forms
of leukemia (24, 25). As2O3 is often considered to be a less toxic
alternative to traditional chemotherapeutic agents. In fact, clinical
studies have been published on the treatment of more than 1,100
promyelocytic leukemia patients with As2O3 (26), and the side
effects of the current course of treatment (5 weeks of daily doses)
are relatively mild, including dermatological issues, fatigue, and
nausea. A comparatively severe cardiac side effect is prolonged QT
interval; however, this effect is reversible after treatment ceases
and has not led to any As2O3-associated deaths (25). Furthermore,
oral preparations of As2O3 are being investigated and appear to
avoid this complication (23). These clinical features make As2O3 a
promising stressor to consider for use in enhancing rAAV trans-
duction.
Numerous studies have worked to define the mechanisms by
which As2O3 acts to treat promyelocytic leukemia. When cells are
treated with As2O3, it is taken up through aquaglyceroporins and
then acts on a molecular level by binding thiol ligands from cys-
teine residues (27). On a cellular level, As2O3 has many effects,
including inducing reactive oxygen species (ROS) formation (28),
inhibiting NF-B activation (29), degrading the promyelocytic
leukemia protein (PML) (30), changing mitochondrial mem-
brane potentials (31), inducing global changes in transcriptional
patterns (32), and, at high doses, inducing apoptosis (24, 33).
Therefore, As2O3 can lead to widespread changes in the cellular
environment. In addition, As2O3 has previously been demon-
strated to have effects on several different viruses. Specifically,
As2O3 increases human immunodeficiency virus (HIV) infection
in nonpermissive cell types but has no effect in permissive cell
types (34–36). Moreover, treatment of patients with As2O3 often
leads to the reactivation of varicella-zoster virus (VZV) and HSV
(37, 38); in fact, the risk of patients developing herpes zoster after
As2O3 treatment is 26%, which is higher than the 20% risk found
with severe immunosuppression after hematopoietic stem cell
transplant (37). Indeed, the high rate of herpes reactivation has led
some groups to proscribe prophylactic acyclovir during As2O3
treatment (23).
As As2O3 affects these other viruses, and chemotherapeutic
agents, such as proteasome inhibitors (6, 39) and topoisomerase
inhibitors (18), have been demonstrated to enhance rAAV trans-
duction, we determined whether As2O3 has an effect on initial
rAAV transduction. We utilized rAAV2 vectors and examined
transduction both in As2O3-treated cells and in vivo. We deter-
mined that transduction of rAAV2 was enhanced in vitro and in
vivo, and that the transduction of several different rAAV serotypes
was also enhanced in vivo. In addition, we determined that As2O3
treatment of cells maintained the accumulation of rAAV2 virions
at the MTOC, and that this effect was dependent on induction of
ROS formation. The enhancement of rAAV transduction by
As2O3 and the mechanisms behind this enhancement have impli-
cations for the enhancement of rAAV-mediated gene delivery and
possibly for the initial infection pathways of other viruses affected
by As2O3.
MATERIALS AND METHODS
Cell culture and chemicals. HEK-293 cells, HeLa cells, human foreskin
fibroblasts immortalized with telomerase (HFF hTERT), and Cos-1 cells
were maintained in Dulbecco’s modified Eagle medium (DMEM). C-12
cells were maintained in minimal essential medium (MEM) alpha without
ribonucleosides and deoxyribonucleosides, and Cho-K1 cells were main-
tained in Ham’s F-12 medium. Cells utilized in confocal microscopy ex-
periments were maintained in MEM without phenol red and were sup-
plemented with 2 mM L-glutamine and 1 MEM nonessential amino
acids for at least two passages before imaging. All cells were maintained at
37°C and 5% CO2, and medium was supplemented with 10% fetal bovine
serum, 100 U/ml penicillin, and 100 g/ml streptomycin.
As2O3 (Sigma-Aldrich) was prepared for in vitro use as a 1 mM solu-
tion in 200 mM NaOH and compared to a vehicle control of the same pH.
For in vivo use, a 50 mg/ml solution of As2O3 in 1 M NaOH was prepared,
diluted to 0.5 mg/ml in phosphate-buffered saline (PBS), and brought to
a neutral pH with HCl. A proteasome inhibitor, MG-132 (Calbiochem),
was prepared at 10 mM in dimethylsulfoxide (DMSO). N-acetyl-L-cys-
teine (NAC; Sigma-Aldrich) was prepared at 500 mM in PBS. Dihydro-
ethidium (DHE; Sigma-Aldrich) was prepared at 10 mM in DMSO.
Virus production. rAAV vector was produced in HEK-293 cells as
previously described (40). Briefly, rAAV was prepared by transfection of
HEK-293 cells with pXX680, a pXR plasmid (pXR2, pXR6, pXR8, or pXR9
for the different serotypes of rAAV produced), and either pTR-CBA-
EGFP or pTR-CBA-Luc. After 48 h, cells were harvested, lysed, and DNase
treated. For general use, vector was purified on a cesium chloride gradient
and then dialyzed to remove the cesium. To produce pure vector for
fluorescent labeling, the vector was purified on a discontinuous iodixanol
gradient followed by ion-exchange chromatography and dialysis. The ti-
ters of the vectors were determined by quantitative PCR (qPCR) as pre-
viously described (40).
Transduction assays. For transduction experiments, 8  104 cells
were seeded per well of a 24-well plate 16 to 18 h prior to transduction and,
where indicated, were treated with the stated doses of As2O3 or vehicle
control at the time of seeding. Vector was added in fresh media at the
indicated vector dose. For proteasome inhibition experiments, 1 M
MG132 or a DMSO control was added concurrently with transduction.
Cells were harvested by trypsinization at 48 h posttransduction unless
otherwise noted. For flow cytometry, trypsinized cells were resuspended
in 2% paraformaldehyde and analyzed using a Beckman-Coulter CyAn
ADP instrument. Enhanced green fluorescent protein (EGFP) fluores-
cence was measured using a 488-nm excitation laser and 530- to 540-nm
emission filter.
DNA purification and qPCR of viral genome copy number. For
quantification of intracellular vector genome copies (vg), transduced cells
were harvested by trypsinization and washed with PBS, and total DNA was
harvested using the Qiagen DNeasy blood and tissue kit per the manufac-
turer’s instructions. Viral genomes and cellular endogenous control genes
were quantified as previously described (6). Briefly, primers were utilized
to quantitate EGFP (forward, 5=-AGC AGC ACG ACT TCT TCA AGT
CC-3=; reverse, 5=-TGT AGT TGT ACT CCA GCT TGT GCC-3=), lucif-
erase (forward, 5=-AAA AGC ACT CTG ATT GAC AAA TAC3=; reverse,
5=-CCT TCG CTT CAA AAA ATG GAA C-3=), human LB2C1 (forward,
5=-GTT AAC AGT CAG GCG CAT GGG CC-3=; reverse, 5=-CCA TCA
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GGG TCA CCT CTG GTT CC-3=), mouse -actin (forward, 5=-TGG
CAC CAC ACC TTC TAC AAT-3=; reverse, 5=-AGG CAT ACA GGG ACA
GCA CA-3=), and hamster glyceraldehyde-3-phosphate dehydrogenase
(GAPDH) (forward, 5=-CGT ATT GGA CGC CTG GTT AC-3=; reverse,
5=-GGC AAC AAC TTC CAC TTT GC-3=). The human LB2C1 primer set
was also used to quantitate Cos-1 cellular genomes. All reactions were run
with Sybr Green master mix (Roche Applied Sciences) on a Roche Light-
Cycler 480. The following run protocol was used: 95°C for 10 min, fol-
lowed by 45 cycles of 95°C for 10 s, 60°C for 10 s, and 72°C for 10 s.
Absolute quantification was performed based on second-derivative max-
imum comparisons to standard curves of plasmid DNA (EGFP and lucif-
erase) or untransduced cellular DNA.
Cell cycle analysis. For analysis of the proportion of cells in each stage
of the cell cycle, cells were treated overnight with As2O3 as described
for transduction assays and then harvested at the conclusion of As2O3
treatment. Propidium iodide staining was performed as has been previ-
ously described (41), with slight modifications. Briefly, cells were washed
twice with PBS plus 0.1% fetal bovine serum and then fixed in ethanol
overnight. After fixation, cells were washed and then resuspended in pro-
pidium iodide staining solution (40 g/ml propidium iodide [Sigma-
Aldrich] in PBS with 3.8 mM sodium citrate) and 0.5 g RNase A (Sigma-
Aldrich) and allowed to stain for at least 3 h at 4°C. DNA content was
analyzed by flow cytometry at a low rate of flow. Flow cytometry was
performed on a Beckman-Coulter CyAn ADP instrument using a 488-nm
excitation laser and a 613- to 620-nm emission filter.
Capsid labeling and confocal microscopy. rAAV2 virions were fluo-
rescently labeled with Cy5 and used for confocal imaging as previously
described (42), with slight modifications. Briefly, pure rAAV2 virions
were incubated with 5,000 molecules of mono-NHS-Cy5 (GE Healthcare)
per vector genome for 45 min at room temperature and then extensively
dialyzed to remove excess dye. The titer of the labeled vector was deter-
mined by qPCR. For confocal imaging experiments, Cho-K1 cells were
seeded and treated with As2O3 as described for transduction experiments
on poly-L-lysine-coated coverslips. Cy5-labeled rAAV2 was added to the
cells at 10,000 vg/cell 16 to 18 h after seeding. At the time of harvest, cells
were washed three times with PBS, fixed with 2% paraformaldehyde for 15
min at room temperature, washed 2 times with PBS and 1 time with
double-distilled H2O, and mounted on slides with ProLong Gold Anti-
fade Reagent with 4=,6-diamidino-2-phenylindole (DAPI) (Molecular
Probes).
For confocal microscopy, rAAV2 virion localization was analyzed with
a Zeiss LSM 710 spectral confocal laser-scanning microscope using a Plan
Apochromat 63/1.40-numerical-aperture oil objective. Z stacks of 12 to
14 focal planes were acquired at 0.63-m Z intervals, and these images
were used to create three-dimensional (3D) reconstructions. Images were
deconvoluted using the AutoQuant X3 program (MediaCybernetics) to
perform 3D blind adaptive point spread function deconvolution. The
IMARIS software package (Bitplane AG) was used to create 3D projec-
tions of the stacks.
Reactive oxygen species quantification and scavenging. Cells were
seeded and treated as described for transduction experiments. For ROS
scavenging experiments, NAC was added to cells at the indicated doses at
the time of As2O3 treatment. NAC and As2O3 were removed at the time of
transduction, and transduction was assayed as described above. Quanti-
fication of ROS levels by DHE staining has been previously described (43).
Briefly, cells were harvested by trypsinization 16 to 18 h after treatment,
washed twice with PBS, and then incubated for 30 min at 37°C in 10 M
DHE in PBS. After incubation, the cells were washed once with PBS. Flow
cytometry was performed on the Beckman-Coulter CyAn ADP instru-
ment using a 488-nm excitation laser and a 575- to 625-nm emission filter.
In vivo transduction assays. All mouse experiments were conducted
in accordance with the policies of the University of North Carolina at
Chapel Hill’s Institutional Animal Care and Use Committee. For in vivo
transduction experiments, age- and strain-matched female mice (Jackson
Laboratories) were treated with 5 g/g/day As2O3 or a PBS vehicle control
by intraperitoneal (i.p.) injection for 5 days. On the third day of treatment,
mice were transduced with the indicated dose of AAV vector in PBS by
retro-orbital injection. Live imaging of luciferase expression from AAV
vectors has been previously described (44). Briefly, mice were given 150
mg/kg D-luciferin (Caliper LifeSciences) by i.p. injection, and after 5 min,
luminescence was measured using the IVIS-Lumina imaging system (Cal-
iper LifeSciences). The Igor Pro 3.0 software was used to quantitate lumi-
nescence signals.
RESULTS
Arsenic trioxide treatment increases the percentage of cells
transduced with rAAV2. To expand our knowledge of AAV’s re-
sponses to cellular stressors, we set out to determine whether
As2O3 treatment had an effect on rAAV2’s initial transduction.
We first treated HEK-293 cells overnight with various doses of
As2O3, transduced them with rAAV2-EGFP, and assayed the per-
centage of cells transduced after 48 h. After As2O3 treatment, we
observed a dose-dependent increase in the percentage of cells
transduced by rAAV2 (Fig. 1A), with a maximum increase of 19.4-
fold in the 8 M As2O3 group. Due to toxicity from higher As2O3
FIG 1 HEK-293 cells transduced by rAAV2 after As2O3 treatment. HEK-293
cells were treated overnight with As2O3 or a vehicle control and then trans-
duced with rAAV2-CBA-EGFP. (A) Cells were treated with the indicated dose
of As2O3 and transduced with 500 vg/cell rAAV2. The percentage of cells trans-
duced at 48 h posttransduction is shown as the fold increase compared to the
level for the no-treatment group. (B) The numbers of vector genome copies
per cell present and percentages of cells transduced were assayed at 48 h post-
transduction following the indicated treatment and transduction with 500
vg/cell. Values are indicated as fold increase compared to results for the no-
treatment group. (C) Cells were treated and transduced as described for panel
B, harvested at the indicated time points, and assayed for the percentage of cells
transduced. Values are indicated as fold increase compared to the no-treat-
ment group at 24 h. NT, no treatment; Veh, vehicle. (D) After treatment as
described for panel B, cells were transduced with the indicated doses of rAAV2,
and the percentage of cells transduced was assayed 48 h posttransduction.
Values represent the percentage of the maximum value reached in each exper-
iment. Data shown are the means from at least 3 independent experiments;
error bars represent the standard errors of the means (SEM). P  0.05 (*) and
P  0.005 (***) based on comparisons of sample means by the Student t test.
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concentrations (data not shown), further experiments were con-
ducted in HEK-293 cells with the 4 M As2O3 dose to verify that
the increase in the percentage of cells transduced observed with
As2O3 treatment was due to an increase in transduction and not an
increase in transgene expression. We assayed the numbers of vec-
tor genomes present in the cells 48 h posttransduction and deter-
mined that the increase in the intracellular vector genome copy
number correlated very well with the percentage of cells trans-
duced (Fig. 1B). In addition, we observed no increase in transgene
expression from a plasmid carrying the transgene cassette follow-
ing As2O3 treatment (data not shown). To determine whether
As2O3’s transduction effect is stable over time, we treated the cells
as described above, assayed transduction from 24 to 96 h post-
transduction, and determined that As2O3 increased transduction
to a similar extent at all of the time points assayed (Fig. 1C). Fur-
thermore, we also investigated whether the effect of As2O3 would
be maintained at a range of vector doses. In fact, we observed
significant increases in transduction with As2O3 treatment with
rAAV2 doses from 250 to 4,000 vg/cell (Fig. 1D). The increase in
the numbers of vector genomes per cell in both the vehicle-treated
and As2O3-treated cells was linear (R
2 values of 0.996 and 0.999,
respectively).
The effects of As2O3 treatment on HIV infection can only be
observed in nonpermissive cell types (34–36); therefore, given the
increase in rAAV2 transduction observed with As2O3 treatment in
HEK-293 cells, we tested the effect of As2O3 in other human and
nonhuman cell lines. We optimized rAAV2 doses to result in 5 to
10% of cells transduced without treatment and performed dose
curves to identify doses of As2O3 capable of increasing rAAV2
transduction without overt toxicity (data not shown), as sensitiv-
ity of cells to As2O3 varies based on cellular glutathione levels (28).
In HeLa cells, which have been commonly utilized as a model cell
line for exploring AAV biology, we observed a 2.4-fold increase in
AAV2 transduction following As2O3 treatment that correlated
well with an increase in the vector genome copy number (Fig. 2A).
We then investigated a human diploid cell line, HFF hTERT. In
these cells, we observed a 4.2-fold increase in the percentage of
cells transduced with rAAV2; however, the increase in the vector
genome copy number was smaller, although it was still significant
(Fig. 2B).
To determine whether the effect of As2O3 on rAAV2 transduc-
tion is restricted to human cells, we investigated the effect of As2O3
in several nonhuman cell lines. In Cos-1 cells, which are of non-
human primate origin, we observed a 2.7-fold increase in the per-
centage of cells transduced that correlated well with an increase in
the vector genome copy number (Fig. 2C). As rAAV2 is liver
tropic, we next investigated the effect of As2O3 on transduction of
a mouse hepatoma-derived cell line, C-12. As2O3 treatment in-
creased the percentage of cells transduced with rAAV2 by 4.2-fold
in this cell line, and this increase correlated well with the increase
in the vector genome copy number (Fig. 2D). Finally, we tested the
FIG 2 rAAV2 transduction after As2O3 treatment of several human and nonhu-
man cell lines. Cells were treated overnight with the indicated doses of As2O3 and
a cell line-specific dose of rAAV2. The percentage of cells transduced (left) and
numbers of vector genomes per cell (right) were assayed 48 h posttransduction
in HeLa cells transduced with 250 vg/cell (A), HFF hTERT transduced with
5,000 vg/cell (B), Cos-1 cells transduced with 1,000 vg/cell (C), C-12 cells
transduced with 3,000 vg/cell (D), and Cho-K1 cells transduced with 5,000
vg/cell (E). Values represent the fold change compared to results for no treat-
ment and are the means from at least 3 independent experiments. Error bars
represent the SEM. P  0.05 (*), P  0.01 (**), and P  0.005 (***) based on
comparisons of sample means by the Student t test.
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effect of As2O3 in Cho-K1 cells, which are hamster cells with nor-
mal protein modification pathways, and observed a 5.0-fold in-
crease in the percentage of cells transduced with As2O3 treatment,
although the increase in the vector genome copy number was
smaller (Fig. 2E). Therefore, the increase in transduction observed
after As2O3 treatment is not restricted to a specific cell type or to a
specific species origin.
Arsenic trioxide acts in the first 24 h of transduction through
a postentry mechanism. To gain mechanistic insights into the
actions of As2O3 on rAAV2 transduction, we first examined the
effect of As2O3 on self-complementary rAAV2 transduction,
which does not require second-strand DNA synthesis. We deter-
mined that As2O3 caused a similar increase in rAAV transduction
with both single-stranded (ssAAV) and self-complementary
(scAAV) rAAV, suggesting that As2O3 affects a step in rAAV trans-
duction prior to second-strand synthesis (Fig. 3A). To determine
when this effect occurs, we investigated the effect of the timing of
As2O3 addition on the transduction of rAAV2. We treated cells
with As2O3 from 18 h before transduction or 0, 3, 7, or 24 h
posttransduction to the time of harvest and assayed the percentage
of cells transduced with rAAV2. We observed that the majority of
the As2O3 effect was confined to pretreatment and treatment
within the first 24 h of transduction (Fig. 3B). Since As2O3 acts in
the first 24 h of transduction (Fig. 3B) and the vector genome copy
number is increased similarly to the percentage of cells transduced
at 48 h posttransduction (Fig. 1B), we then investigated the change
in numbers of intracellular vector genomes over time. The vector
genome copy number was similar between As2O3- and vehicle-
treated cells until 15 to 18 h posttransduction; however, vector
genome copy number in the vehicle-treated cells then decreased at
a higher rate than that of As2O3-treated cells (Fig. 3C). The differ-
ence in the percentage of cells transduced at each time point cor-
related well with the difference in the vector genome copy num-
bers (data not shown). These data suggest that the effect of As2O3
occurs after rAAV2 has entered the cell and prior to second-strand
DNA synthesis. To determine whether the increase in rAAV vector
genome copy number or transduction is due to inhibition of the
cell cycle following As2O3 treatment, we treated cells overnight
with As2O3 or a vehicle control and then measured the proportion
of cells in each stage of the cell cycle. We determined that there was
very little or no change in the percentage of cells in each cell cycle
stage following As2O3 treatment (Fig. 3D), and that any changes
were within the range of variability between experiments. These
data are substantiated by our toxicity assays, in which equal num-
bers of total and viable cells were observed following As2O3 treat-
ment (data not shown). Given these data, it is unlikely that the 3-
to 4-fold changes in rAAV transduction and vector genome copy
number could result from a decrease in cell division rates. There-
fore, these data suggest that the increase in vector genome copy
number and in rAAV transduction is not due to cell cycle arrest
but instead is due to another change in the intracellular environ-
ment.
Increased vector copy number is also observed with protea-
some inhibition of AAV-transduced cells, which induces the nu-
cleolar localization of rAAV2 (6); therefore, we investigated
whether the effects of proteasome inhibition and As2O3 treatment
on AAV2 transduction overlap. When cells were pretreated with
As2O3 and then cotreated with a proteasome inhibitor, MG132,
and rAAV2, there was no additional increase in the percentage of
cells transduced between MG132 treatment and MG132/As2O3
treatment. However, the median fluorescence intensity (MFI) of
the positive cells was greater for the combined MG132/As2O3
treatment than for MG132 alone (Fig. 3E). As both of these drugs
appear to act through postentry mechanisms, this suggests that the
combination of the drugs leads to more successful intracellular
trafficking despite the lack of increase in the numbers of cells
transduced when the drugs were combined; nevertheless, the ad-
ditional increase in the MFI with MG132 and As2O3 treatment
FIG 3 Mechanistic insights regarding rAAV2 transduction after As2O3treatment.
(A) HEK-293 cells were treated overnight with 4 M As2O3 or a vehicle control
and then transduced with 500 vg/cell single-stranded rAAV2 (ssAAV) or 100 vg/
cell self-complementary rAAV2 (scAAV), and the percentage of cells transduced
was assayed at 48 h posttransduction. (B) HEK-293 cells were treated with 4 M
As2O3 or a vehicle control starting at the indicated times and continuing to the
time of harvest, 48 h posttransduction with 500 vg/cell rAAV2, and the percentage
of cells transduced was assayed. (C) HEK-293 cells were treated overnight with 4
M As2O3 or vehicle and then transduced with 1,000 vg/cell rAAV2, and numbers
of intracellular vector genomes were assayed at the indicated times posttransduc-
tion. (D) HEK-293 cells were treated overnight with 4 M As2O3 or a vehicle
control and then stained with propidium iodide to determine the percentage of
cells in each cell cycle stage. (E) HEK-293 cells were treated as described for panel
C, and 1 M MG132, a proteasome inhibitor, or a vehicle control was added at the
time of transduction. Cells were harvested at 24 h posttransduction, and the per-
centage of GFP-positive cells and the median fluorescence intensity of the positive
cells were assayed. Data representative of three independent experiments is shown.
Error bars represent 1 standard deviation (SD). *, P  0.05 based on the nonpara-
metric Kruskal-Wallis test.
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suggests at least partially independent mechanisms for these two
drugs.
Arsenic trioxide treatment stabilizes accumulations of
rAAV2 virions over time and acts through reactive oxygen spe-
cies formation. To determine whether the lower rate of vector
genome loss we observed occurred on the level of the virion or on
the level of the genome, we transduced Cho-K1 cells, which are
amenable to imaging techniques, with fluorescently labeled
rAAV2 virions and tracked their intracellular trafficking through
confocal microscopy after either vehicle treatment or As2O3 pre-
and cotreatment. Previous observations have suggested that rAAV
traffics to the perinuclear region on microtubules where it accu-
mulates, and then some portion of virions proceed to the nucleus,
where uncoating occurs (5, 6, 45). At 8 h posttransduction, a time
at which the vector genome copy number was similar between
vehicle- and arsenic-treated HEK-293 cells (Fig. 3A), we observed
very little difference in the localization of virions between the ve-
hicle-treated (Fig. 4A) and As2O3-treated (Fig. 4B) cells. However,
at 24 h posttransduction, although we observed some perinuclear
accumulation of virions with vehicle treatment (Fig. 4C), much
larger perinuclear accumulations of virions were present in
As2O3-treated cells (Fig. 4D). This effect was even more pro-
nounced at 32 h posttransduction, when many vehicle-treated
cells had few or no AAV virions remaining (Fig. 4E), but As2O3-
treated cells still had large, condensed perinuclear accumulations
of virions (Fig. 4F). We observed no clear differences in the
amount or localization of intact virions in the nucleus at any of
these time points. Together, these data suggest that As2O3 pre-
vents the loss of intracellular rAAV2 virions during transduction.
Many cellular effects of As2O3 are mediated through the for-
mation of ROS (reviewed in reference 46). Consequently, we in-
vestigated whether the effect of As2O3 on rAAV2 transduction was
mediated by ROS formation. When cells were treated with in-
creasing doses of As2O3, we observed a dose-dependent increase in
the levels of intracellular ROS, as evidenced by increased red flu-
orescence following DHE staining of treated cells (Fig. 5A). Spe-
cifically, significant increases in the MFI were observed with the 2,
4, and 8 M As2O3 treatments (Fig. 5C). As the dose-dependent
increase in ROS mirrors the dose-dependent increase in AAV2
transduction following As2O3 treatment, we then investigated
whether inhibiting ROS formation, by treating cells with
N-acetyl-L-cysteine (NAC), would inhibit the transduction effects
of As2O3. We treated cells overnight with As2O3 and NAC, trans-
duced them with rAAV2, and measured the levels of ROS present
at the time of transduction and the percentage of cells transduced
48 h posttransduction. Although treatment with As2O3 induced
ROS formation, treatment with NAC caused a dose-dependent
decrease in ROS formation, where 10 mM NAC treatment of
As2O3-treated cells resulted in a population that overlaid that of
the vehicle control (Fig. 5B). When we assayed for transduction,
we observed a dose-dependent decrease in transduction following
NAC and As2O3 cotreatment compared to treatment with As2O3
alone (Fig. 5D). NAC had no effect on the transduction of vehicle-
treated cells. These data suggest that As2O3 acts through the for-
FIG 4 Subcellular localization of rAAV2-Cy5 virions after As2O3 treatment. Cho-K1 cells were treated with a vehicle control (A, C, and E) or 8 M As2O3 (B,
D, and F) from 18 h pretransduction to the time of harvest and were transduced with 10,000 vg/cell rAAV2-Cy5. Cells were fixed at 8 h posttransduction (A and
B), 24 h posttransduction (C and D), or 32 h posttransduction (E and F). The localization of rAAV virions was determined by confocal microscopy, and
representative deconvoluted 3D projections are shown. Cy5 signal is shown in yellow; DAPI signal is shown in purple. Scale bars represent 5 m.
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mation of ROS, leading to a decrease in the loss of rAAV2 virions
over time and, thus, to increased AAV transduction.
Arsenic trioxide increases rAAV2 transduction in vivo but
does not change tropism. To determine whether the increase in
rAAV2 transduction we observed with As2O3 in vitro could be
replicated in vivo, we treated mice for 5 days with a dose of 5
g/g/day As2O3, which replicates the levels of serum As2O3 ob-
served in promyelocytic leukemia patients treated with this drug
(47, 48). With this dose of As2O3, we observed no weight loss or
overt toxicity and no increase in serum liver enzyme levels (ala-
nine aminotransferase [ALT] and aspartate aminotransferase
[AST]) over those of the vehicle control, suggesting a lack of acute
liver toxicity (data not shown). We transduced mice systemically
with 2  1011 vg rAAV2-luciferase on the third day of As2O3
treatment and measured transduction through luciferase live im-
aging. We observed measurable luciferase activity in As2O3-
treated mice as early as 2 days posttransduction, at which time the
activity of vehicle-treated mice was close to background levels
(Fig. 6A). By day 7 posttransduction, all As2O3-treated mice were
expressing strongly, while the vehicle-treated mice were showing
early, low levels of expression (Fig. 6B). Furthermore, when we
quantified expression in the whole mouse (Fig. 6C) or the area of
the liver alone (Fig. 6D), we observed significant increases in
transduction at 5 to 12 days posttransduction. In fact, at day 5
posttransduction, liver expression in As2O3-treated mice was
19.3-fold greater than that of the vehicle-treated mice (Fig. 6D).
These data suggest that As2O3 can increase rAAV2 transduction in
vivo. To confirm the increased expression observed in our live
imaging data, we harvested the organs from mice at 14 days post-
transduction and performed biodistribution experiments. In the
liver, we observed a 3.8-fold increase in normalized luciferase ac-
tivity with As2O3 treatment and minimal expression in the other
organs tested (data not shown). Furthermore, analysis of vector
genome copy numbers suggested no changes in vector tropism
due to As2O3 treatment (data not shown). These data suggest that
As2O3 can increase rAAV2 transduction in vivo without altering
vector tropism.
Arsenic trioxide increases the transduction of several sero-
types of AAV in vivo. To determine whether As2O3’s effect is
specific to rAAV2 or can be applied to other rAAV serotypes, we
treated mice with As2O3 as before, transduced them with 1  10
11
vg rAAV6, rAAV8, or rAAV9, and assayed transduction by lucif-
erase live imaging. With rAAV6, we observed a clear increase in
transduction at day 7 posttransduction (Fig. 7A), which could also
be observed at 14 days posttransduction (data not shown). Quan-
tification of this increase demonstrated a 5.5-fold enhancement at
day 7 (Fig. 7B). With rAAV8, we observed an enhancement of
transduction from As2O3 treatment at day 2 posttransduction
(Fig. 7C), which was quantified at 3.0-fold (Fig. 7C); however, this
enhancement was not observed at later time points (data not
shown). Finally, with rAAV9, we observed an enhancement of
transduction at day 5 posttransduction (Fig. 7E), which was quan-
tified at 4.2-fold (Fig. 7F). In fact, As2O3 enhanced in rAAV9
transduction from 2 days posttransduction through 3 weeks post-
transduction (Fig. 7G and H and data not shown). Therefore, the
enhancement of transduction caused by As2O3 treatment is not
unique to rAAV2 but can also be observed with several other se-
rotypes of rAAV.
DISCUSSION
In this study, we investigated the effect of As2O3 on the initial
transduction of rAAV vectors. We determined that As2O3 in-
creased rAAV2 transduction both in vitro and in vivo and that,
with As2O3 treatment, perinuclear accumulations of rAAV virions
were maintained over time, leading to the increase in the intracel-
lular vector genome copy numbers observed during transduction.
We observed increased rAAV2 transduction with As2O3 at several
vector doses and time points and in several cell lines with different
tissue and species origins, suggesting that the effect of As2O3 on
rAAV transduction is widespread. As the increased numbers of
cells transduced correlated with an increase in vector genome
copy number (Fig. 1B) and As2O3 had no effect on transgene
FIG 5 Role of ROS in the rAAV2 transduction effects of As2O3. (A) HEK-293
cells were treated overnight with no treatment (red), 1 M As2O3 (blue), 2 M
As2O3 (black), 4 M As2O3 (purple), or 8 M As2O3 (orange), and ROS were
measured with DHE. A histogram of fluorescence intensity is shown. (B) HEK-
293 cells were treated overnight with a vehicle control (red) or 4 M As2O3
(blue) and with PBS (solid line), 5 mM NAC (small dashed line), or 10 mM
NAC (intermediate dashed line) to scavenge ROS. ROS were measured with
DHE, and a histogram of fluorescence intensity is shown. The curve represent-
ing As2O3 ad 10 mM NAC treatment is shaded solid blue in the histogram. (C)
Cells were treated as described for panel A, and the median fluorescence in-
tensity was plotted versus As2O3 concentration. (D) Cells were treated as de-
scribed for panel B and then transduced with 500 vg/cell rAAV2, and the
percentage of cells transduced was assayed at 48 h posttransduction. Data are
representative of three independent experiments. Error bars represent 1 SD. *,
P  0.05 based on the Kruskal-Wallis test.
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expression independent of rAAV (data not shown), we deter-
mined that the effect of As2O3 on rAAV transduction occurs at a
step in transduction prior to gene expression. In addition, the fold
increase in rAAV transduction caused by As2O3 treatment was
stable from 24 to 96 h posttransduction (Fig. 1C) and was ob-
served in vivo in cell types which divide very slowly (Fig. 6 and 7);
this suggests that the increase in transduction observed was not
due to any possible difference in cell division rates, as, in this case,
we would expect the difference in transduction to be minimal in
vivo and, in vitro, to increase over time as vector copies were di-
luted in untreated cells. Furthermore, we analyzed the portion of
cells in each stage of the cell cycle following As2O3 treatment and
observed no indications of cell cycle arrest (Fig. 3D). Instead, this
suggests that the difference in transduction and in intracellular
genome copy number is due to a difference in the intracellular
transduction pathway of rAAV. Consequently, we investigated the
intracellular fate of the rAAV through both molecular and imag-
ing techniques.
Our data demonstrate that the intracellular vector genome
copy number was similar between vehicle- and As2O3-treated cells
out to 15 to 18 h posttransduction, at which point the vector
genome copy number decreased more quickly in vehicle-treated
cells than in As2O3-treated cells (Fig. 3C). This correlates well with
our confocal imaging data, which demonstrate an increased per-
sistence of the perinuclear accumulation of rAAV virions in
As2O3-treated cells (Fig. 4). These data suggest a model in which,
in both As2O3-treated and untreated cells, rAAV virions enter the
cell and are trafficked along microtubules to the MTOC, where
they accumulate (5, 45). At the MTOC, the virions can continue
their trafficking either productively by trafficking to the nucleus or
nonproductively by eventually being targeted for degradation by
proteasomal or lysosomal means. Without treatment, many rAAV
virions are targeted for degradation, leading to relatively few viri-
ons continuing on their productive pathway (Fig. 8A). With
As2O3 treatment, fewer virions are degraded, leading to viral sta-
bility in the perinuclear region and an increase in the productive
trafficking of virions (Fig. 8B). This difference in the trafficking
pathways then causes the difference in vector genome copy num-
ber and transgene expression observed.
The assertion that virions maintained at the perinuclear region
FIG 6 rAAV2 transduction effects of As2O3 in vivo. Five- to 6-week-old BALB/c mice were treated for 5 days with 5 g/g/day As2O3 or a PBS vehicle control by
intraperitoneal injection and transduced with 2  1011 vg rAAV2-CBA-luciferase on the third day of treatment. Images from luciferase live imaging at 2 days (A)
and 7 days (B) posttransduction are shown (5 min of exposure). Quantification of luciferase activity from live imaging from 2 to 12 days posttransduction from
the whole mouse (C) and from the area of the liver (D) is shown with fold increase values of As2O3 compared to those for the vehicle (n  5). Error bars represent
1 SD. *, P  0.05 based on the Kruskal-Wallis test.
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are capable of continuing their trafficking productively is sup-
ported by recent work demonstrating that the perinuclear region
acts as a sink for rAAV particles and, thus, that disruption of the
MTOC shortly after rAAV has accumulated can lead to increased
rAAV transduction (P. J. Xaio and R. J. Samulski, unpublished
data). In this study, however, we are examining later time points
during which perinuclear accumulations are generally being
cleared and are preventing virion degradation at the perinuclear
region. Taken together, the previous work and our data suggest
that maintaining the perinuclear accumulation of rAAV, rather
than allowing it to be degraded over time, allows more virions to
escape from this region and continue down a productive trans-
duction pathway. In addition, previous work has suggested that
rAAV virions are carried on microtubules in endosomal compart-
ments to the MTOC, where endosomal escape presumably occurs
(5). This suggests that if virions remain in the perinuclear region
FIG 7 Transduction from several serotypes of rAAV after As2O3 treatment. Five- to 6-week-old C57BL/6 mice were treated for 5 days with 5 g/g/day As2O3 or
a PBS vehicle control by intraperitoneal injection and transduced with 1  1011 vg rAAV6-CBA-luciferase (A and B), rAAV8-CBA-luciferase (C and D), or
rAAV9-CBA-luciferase (E, F, G, and H) on the third day of treatment. Images from live luciferase imaging are shown on day 7 for rAAV6 (A) (5 min of exposure),
day 2 for rAAV8 (C) (5 min of exposure), day 5 for rAAV9 (E) (1 min of exposure), and day 21 for rAAV9 (G) (1 min of exposure). Quantification of luciferase
activity from live imaging is shown at the same time points for rAAV6 (B) (n  4), rAAV8 (D) (n  4), and rAAV9 (F and H) (n  3). Error bars represent one
SD. *, P  0.05 based on the Kruskal-Wallis test.
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for longer periods of time, more virions can be released from
endosomes and escape perinuclear retention to continue on a pro-
ductive trafficking pathway to the nucleus.
Proteasome inhibitors, such as MG132, have previously been
demonstrated to lead to increased nucleolar accumulation of
rAAV virions and to increased intracellular vector genome copy
number, leading to higher transduction (6). Given the probable
role of degradation in the effect of As2O3 on rAAV transduction,
we find it interesting that As2O3 and MG132 have at least partially
independent effects on rAAV transduction (Fig. 3E) and appear to
act at different levels on the intracellular trafficking of rAAV (Fig.
4) (6). This suggests the following possibilities: (i) rAAV virions
are being degraded in significant numbers by a nonproteasomal
mechanism that As2O3 affects, leading to the separate roles of
MG132 and As2O3; (ii) MG132 increases rAAV transduction
through a mechanism that is separate from inhibition of the pro-
teasome, so the decrease in degradation observed with As2O3 is
separated from that of MG132; or (iii) MG132 and As2O3 each
have partial effects on the proteasomal degradation of rAAV in
separate steps in intracellular trafficking, perhaps in perinuclear
degradation for As2O3 and in nuclear degradation for MG132,
leading to their separate effects. We are currently investigating the
specific mechanisms of rAAV degradation modified with As2O3
treatment, which should lend clarity to these issues.
In addition to rAAV2, we investigated the ability of As2O3 to
enhance the transduction of several other rAAV serotypes in vivo.
As2O3 enhanced the transduction of rAAV6, rAAV8, and rAAV9
in vivo early after transduction (Fig. 7); however, the kinetics of
the enhancement varied based on the serotype. Specifically, As2O3
enhanced the transduction of rAAV2 and rAAV9 at time points
ranging from 2 days posttransduction to 14 days or more post-
transduction, while rAAV8’s transduction is enhanced at 2 days
posttransduction but not at later time points (Fig. 6 and 7 and data
not shown). This is interesting, as it suggests that there is capsid
specificity in the response to As2O3, perhaps derived from differ-
ences in intracellular trafficking patterns or efficiencies with dif-
ferent serotypes. Although the intracellular trafficking of rAAV2 is
the most thoroughly studied, several reports have begun to com-
pare the trafficking pathways of different rAAV serotypes. For
instance, rAAV1 and rAAV5 can traffic to the nucleus of HeLa
cells more quickly than rAAV2 but have lower levels of transduc-
tion due to either poor uncoating or rapid degradation, respec-
tively (49). In addition, a recent report suggested that, perhaps due
to differences in receptor usage, rAAV2 and rAAV8 differentially
traffic through endosomal compartments and have different re-
quirements for endosomal escape (50). Specifically, rAAV2 is re-
ported to traffic through early, recycling, and late endosomes and
to require low pH for endosomal escape, while rAAV8 does not
traffic through late endosomes, only early and recycling endo-
somes, and low pH is not sufficient for its endosomal escape. The
difference in the kinetics of As2O3’s effect on the transduction of
rAAV2 and rAAV8 suggests a role for endosomal trafficking in the
As2O3 effect. Determining the role of endosomes in As2O3’s trans-
duction effect and determining the specific regions of the capsid
responsible for the differences in the As2O3 effect will be interest-
ing avenues to pursue in the future.
As2O3 has well-known effects on cellular concentrations of
ROS, and ROS are thought to act as intermediates in some of
As2O3’s other cellular effects; therefore, we investigated whether
the effects of As2O3 on rAAV2 transduction were mediated
through ROS formation. We determined that As2O3 causes a
dose-dependent increase in ROS that corresponds well to the
dose-dependent increase in rAAV2 transduction, and that inhib-
iting the formation of ROS inhibits As2O3’s enhancement of
rAAV2 transduction (Fig. 5). Interestingly, ROS formation has
previously been demonstrated to be important for enhancement
of rAAV transduction by hydroxyurea and UV light, and a role for
second-strand DNA synthesis was suggested (8, 51), although
later reports questioned this assertion (6, 52). As we determined
that As2O3 can enhance the transduction of self-complementary
rAAV2 (Fig. 3A), which does not require second-strand synthesis,
and also observed changes in earlier steps in transduction (Fig. 4),
it is unlikely that As2O3 is acting through enhancement of second-
strand synthesis. Furthermore, although hydroxyurea acts
through ROS, similar to As2O3, it increases the nuclear localiza-
tion of rAAV2 without increasing the intracellular vector genome
FIG 8 Model for effect of arsenic trioxide on AAV transduction. (A) In un-
treated cells, rAAV enters the cell through receptor-mediated endocytosis and
is trafficked to the MTOC. At the MTOC, virions can be retained for a time or
proceed to the nucleus; however, the majority of the virions are degraded
through mechanisms possibly involving the proteasome or lysosomes, and the
perinuclear accumulation clears by 32 h posttransduction. (B) In As2O3-
treated cells, cell entry and trafficking to the MTOC occurs as described for
panel A; however, As2O3, through ROS formation, acts to block the degrada-
tion of the virion. Consequently, more virions continue on in the transduction
pathway, ultimately leading to greater transgene expression.
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copy number (6), whereas As2O3 increases vector genome copy
number (Fig. 1B) and acts at an earlier step in transduction (Fig.
4). This suggests that, depending on the initiator, ROS can act on
several different steps in rAAV’s transduction pathway. In this
case, ROS may have a broad role in a number of steps in AAV’s life
cycle.
As2O3 has many effects on the cellular level involving ROS
formation, which may play a role in its enhancement of rAAV
transduction. For instance, As2O3 has been shown to inhibit
NF-B activation by directly binding a cysteine residue on the
activation loop of the protein (29); however, as the concentration
of As2O3 necessary to inhibit NF-B activation was higher than
those used in our studies and the timing of As2O3 addition was
different, the status of NF-B activation in our experiments is
unclear. Several studies have suggested a positive role for NF-B
activation in rAAV transduction (52, 53), and several other ROS
generators, such as UV light and H2O2, have been shown to in-
crease NF-B activation, although this activation was not neces-
sary for their effects on AAV transduction (51, 52). Nevertheless, it
will be enlightening to explore the role of NF-B in As2O3-medi-
ated enhancement of rAAV transduction further. Another effect
of As2O3 and ROS is to degrade the promyelocytic leukemia pro-
tein (30), which has well-known cell-intrinsic antiviral activities
against many different viruses (reviewed in reference 54). How-
ever, we observed an increase in rAAV2 transduction with no
apparent change in PML levels or localization, and we observed an
increase in transduction in the absence of PML (data not shown).
These data suggest that PML is not a key factor in the effect of
As2O3 on rAAV transduction. Therefore, identification of the spe-
cific cellular mechanisms responsible for the enhancement of
rAAV transduction upon As2O3 treatment will continue to be an
interesting avenue of research.
As2O3 has several known effects on other viruses, either inhib-
iting or enhancing their replication. As2O3 strongly inhibits hep-
atitis C virus replication through a mechanism that involves ROS
but is independent of PML (55, 56); although the specific mecha-
nism has not been elucidated, this is interesting, as As2O3’s en-
hancement of rAAV transduction is also mediated by ROS and is
independent of PML. Moreover, the replication of several other
viruses is enhanced by As2O3 treatment. As2O3 causes an enhance-
ment of HIV replication only in nonpermissive cell types in a
manner that depends on the expression of TRIM5 and
APOBEC3G (35, 36). It is noteworthy that the effects of As2O3 on
HIV are cell line specific, while the effects on AAV are more gen-
eral, and that As2O3 acts on HIV through two cellular proteins
which are unlikely to, or are known not to, interact with AAV (57).
This suggests that although As2O3 has effects on several viruses,
the effects are caused by widespread, diverse mechanisms.
Interestingly, several lines of evidence have suggested that tri-
valent arsenic can induce lytic replication in alphaherpesviruses
(HSV and VZV), betaherpesviruses (human cytomegalovirus
[HCMV]), and gammaherpesviruses (Epstein-Barr virus [EBV])
(37, 38, 58, 59). Specifically, reactivation of HSV and VZV has
been observed in acute promyelocytic leukemia patients treated
with As2O3 at a rate higher than that found with general immu-
nosuppression and in a manner which is not consistent with reac-
tivation from immunosuppression (37, 38). To our knowledge,
no studies have been published investigating the mechanism for
the reactivation of HSV or VZV in response to As2O3. However,
activation of EBV replication in response to As2O3 was correlated
with the degradation of PML, although no direct evidence of a link
was presented (59), while the induction of HCMV immediate-
early gene synthesis by sodium arsenite, another trivalent arsenic
compound, was suggested to be the result of heat shock protein
activation (58). Overall, the mechanisms for herpesvirus reactiva-
tion following As2O3 treatment remain incompletely understood,
and delving into the mechanisms by which As2O3 enhances the
replication of other viruses may lead to useful insights into her-
pesvirus reactivation. For instance, as cellular degradation path-
ways may play a role in the enhancement of rAAV2 transduction
by As2O3, it would be interesting to determine whether there is a
role for these pathways in As2O3-mediated reactivation of HSV or
VZV.
In addition to elucidating possible mechanisms to explore the
effect of As2O3 on the replication of other viruses, the enhance-
ment of rAAV transduction observed with As2O3 treatment may
become important for gene therapy applications. We observed an
increase in rAAV2 transduction both in vitro (Fig. 1 and 2) and in
vivo in several serotypes of rAAV with no apparent toxicity (Fig. 6
and 7 and data not shown). For some gene therapy applications,
especially those involving systemic gene delivery, low levels of
transgene expression or loss of transgene expression over time
have limited the efficacy observed in clinical settings (60, 61).
Pharmacological treatments are a promising approach to increas-
ing rAAV transduction in order to address these issues, particu-
larly when pharmacological agents currently approved for use in
humans are utilized. In fact, bortezomib, a proteasome inhibitor,
has been used in large-animal models to enhance rAAV transduc-
tion (17); however, the serious and even fatal side effects associ-
ated with this drug makes its clinical use for enhancement of rAAV
transduction problematic (17, 22). For this reason, identifying
other agents, such as As2O3, capable of enhancing rAAV transduc-
tion is important to the clinical applications of rAAV. In addition,
investigating the mechanism behind the increase in transduction
observed with pharmacological treatments may allow us to iden-
tify steps in transduction or cellular factors which limit rAAV
transduction and to design other strategies to circumvent these
difficulties. Therefore, our data demonstrating that As2O3 in-
creases the transduction of rAAV vectors both in vitro and in vivo
and suggesting that it acts to stabilize perinuclear accumulations
of rAAV in a way that is dependent on ROS may broaden our
toolkit for understanding AAV biology and improving its gene
therapy applications. In conclusion, pursuing the biology behind
the effects of As2O3 on rAAV transduction may have important
implications both for AAV-mediated gene therapy and for eluci-
dating the mechanism by which As2O3 affects the replication of
other clinically relevant viruses.
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